Project Grant HT94252510877
- The federal Project Grant award of $537,536.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Michigan is funding research to "TARGET MYCOBIOME METABOLISM TO REPROGRAM THE IMMUNOSUPPRESSIVE PANCREATIC TUMOR MICROENVIRONMENT". The award has a performance period from November 1, 2025 to October 31, 2028 and aims to transform healthcare for military service members, veterans, and the broader public...
- This $248,156 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Regents of the University of Michigan to identify molecular biomarkers for invasive glioblastoma cell states and tumor microenvironment modulation. The award period is from October 1, 2025 to September 30, 2027. As a major research university, the University of Michigan has a diverse portfolio of federal contract and grant awards,...
- The Defense Health Agency awarded a $1,178,939.00 Project Grant to the Regents of the University of Michigan under the Military Medical Research and Development program (CFDA 12.420) to conduct advanced phenotyping research to improve diagnostic, longitudinal assessment, and treatment strategies for deployment-related respiratory disease. The award period is from September 1, 2023 to August 31, 2026. As a U.S. Government Entity and top public research university, the University of Michigan has...
- The Department of Defense's Defense Health Agency awarded a $1,100,747 Project Grant on April 1, 2025 to the Regents of the University of Michigan to conduct research on "Protein Engineering of Antibody-Drug Conjugates to Coordinate the Innate and Adaptive Immune Systems for Curative Responses" under the Military Medical Research and Development program (CFDA 12.420). This research aims to develop innovative medical solutions that address critical health challenges relevant to military...
- This Project Grant award of $546,000.00 from the Defense Health Agency supports research at the Regents of the University of Michigan to develop a novel lectin for targeting T-cell lymphomas. The award is part of the Military Medical Research and Development program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for service members and the public through innovative and impactful research. The 3-year award began on September 1, 2023 and will...
- The Regents of the University of Michigan received a $312,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 2-year grant, awarded on February 1, 2024, supports research to investigate "An Unexpected Role for the Ubiquitin Proteasome System in Repeat Associated Non-AUG Translation." This basic and translational biomedical research aims to advance understanding and treatment of neurological disorders...
- This $1,404,000.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the Regents of the University of Michigan, Office of Research and Sponsored Projects (doing business as the University of Michigan) on September 1, 2023. The funding will support research to target the lipid kinase PIKfyve in neuroendocrine prostate cancer over a 3-year period ending on August 31, 2026. The University of Michigan is a leading U.S....
- The University of Michigan received a $932,498 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct non-invasive central nervous system delivery of immunocytokines for sustained expansion of regulatory T cells and treatment of amyotrophic lateral sclerosis (ALS). The award period runs from June 1, 2025 to May 31, 2027. This research aims to develop innovative medical solutions that address critical health...
- The Defense Health Agency awarded a $607,377 Project Grant to the Regents of the University of Michigan to fund a 2-year research project titled "A NEW IDEA FOR ADVANCING AXITINIB-BASED THERAPY IN RECURRENT AND METASTATIC HNSCC." This grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. The University of Michigan, a leading...
- This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
This $448,133 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Michigan to investigate targeting the mycobiome (fungal microbiome) metabolism to reprogram the immunosuppressive pancreatic tumor microenvironment. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative medical solutions to critical health challenges. The award has a performance period from November 1, 2025 to October 31, 2028. As a leading research university, the University of Michigan has a proven track record of executing diverse federal contract and grant awards across medical research, engineering, and advanced technologies to support government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $448.1k | 8/15/25 |